Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice
fa-facebookfa-linkedinfa-youtube-playfa-rss

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Where Will Kinase Inhibitors Fit into the RA Treatment Mix?

Vanessa Caceres  |  Issue: March 2012  |  March 8, 2012

CHICAGO – Presenters at “Looking Ahead to Kinase Inhibition in Rheumatoid Arthritis” delved into some of the big questions that rheumatology faces with kinase inhibitor use.

The presentation, a session here at the 2011 ACR/ARHP Annual Scientific Meeting held in Chicago in November, gave an overview of the kinase inhibitors currently under investigation. [Editor’s note: This session was recorded and is available via ACR SessionSelect at www.rheumatology.org.]

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Mark Genovese, MD, professor of medicine and co-chief of the division of immunology and rheumatology at Stanford University in Stanford, Calif., focused on which kinase pathways are important in rheumatoid arthritis (RA) and how researchers decide what to target.

“The reality is that it takes good and complex medicinal chemistry followed by in vitro, animal models, and, ultimately, target validation in humans, and a certain degree of luck,” Dr. Genovese said.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

He specifically discussed inhibition of janus (JAK), spleen tyrosine kinase (Syk), phosphodiesterase-4, Bruton’s tyrosine kinase, and phosphoinositide 3-kinase.

Tofacitinib (CP-690550, Pfizer), a JAK kinase inhibitor, is an oral drug for RA that is currently in phase III trials. Studies have examined tofacitinib as monotherapy or combination therapy dosed twice a day. Research has examined dosing ranging from 5 mg to 30 mg. “In the clinical domain, [JAK inhibitors] have been studied in transplants, RA, psoriasis, inflammatory bowel disease, and myelofibrosis,” said Michael E. Weinblatt, MD, John R. Riedman Professor of Medicine in the division of rheumatology, immunology, and allergy at Brigham and Womens Hospital in Boston.

Presenters at the session said trials show that tofacitinib appears to be an effective treatment for RA. “We know tofacitinib is clinically effective and improves patient function and health-related quality of life in disease-modifying antirheumatic drug [DMARD]–incomplete therapies as monotherapy, with methotrexate and other DMARDs, and is comparable to adalimumab in methotrexate inadequate response,” said Roy Fleischmann, MD, clinical professor in the department of internal medicine at the University of Texas Southwestern Medical School in Dallas.

What is not yet known is whether an optimal dose of tofacitinib will be 5 mg or 10 mg, whether the drug requires methotrexate to be effective, whether tofacitinib’s effects are clinically the same as methotrexate’s or better, and whether the drug is more likely to inhibit radiographic progression, Dr. Fleischmann said.

“If a patient fails to achieve response to 5 mg, will they respond to 10 mg? What if they respond well to 10 mg—will the patient respond to 5 mg? If a patient goes into true remission with tofacitinib, can it be withdrawn, and will the patient maintain the same benefit?” Dr. Fleischmann asked.

Other long-term questions with tofacitinib relate to its safety profile, said Dr. Weinblatt. “We have two long-term observations with a small percentage having serious infections and some lab abnormalities that led to drug withdrawal,” he said. “This is an immunomodulating therapy, so seeing infections is not unexpected,” Dr. Weinblatt said. However, studies show that doses above 5 mg appear to be associated with more side effects, he said. This raises questions about differences in response and toxicity between tofacitinib 5 mg and 10 mg, he said.

There is also evidence of lipid elevation with tofacitinib use in some patients, he said.

R788

Presenters also discussed fostamatinib disodium (R788, Rigel Pharmaceuticals), an oral inhibitor of Syk kinase. This drug is currently in phase III studies at twice a day dosing, Dr. Weinblatt said. Fostamatinib has been studied for treatment of lymphoma, lupus, and type 1 diabetes.

Research with fostamatinib in RA has shown efficacy with some side effects, such as loose stools or diarrhea in 20% of subjects and an increase in blood pressure in 25% of subjects in one study. “Twenty-five percent needed antihypertensive therapy or needed to increase their dose [of antihypertensive therapy],” he said. However, at the end of the study, subjects’ blood pressure was identical to baseline.

Dr. Fleischmann said the risk for hypertension is not strong as long as clinicians are aware of the risk and treat it appropriately.

Another question about fostamatinib that has yet to be answered is whether it is efficacious in the same population as tofacitinib, Dr. Fleischmann said.

Looking Ahead to Future Use

Ultimately, time will tell how kinase inhibitors will add to the treatment options for RA, the presenters said. “These agents can be used before methotrexate or another DMARD, after methotrexate or another DMARD, before a biologic, after failure of a tumor necrosis factor–1 [TNF-1] agent, after failure of a second TNF-1, or after failure of one or more other biologic,” Dr. Fleischmann said.

He discussed several possible scenarios for kinase inhibitors. If all studies show efficacy and the cost of these drugs is similar to currently available biologics, then he believes methotrexate will still be the first DMARD used. “It works in a third of patients, and it’s cheap,” he said. “The first agent after methotrexate would be a TNF-1 because of their long history of efficacy and known safety profile. Plus, there is no cost advantage to using the oral agents.”

If efficacy is found with kinase inhibitors but the cost of these agents is less than current biologics, Dr. Fleischmann said, methotrexate still will likely be the first DMARD used, followed by a kinase inhibitor and then a TNF inhibitor.

If new studies do not find that kinase inhibitors are as favorable as TNF-1 or other biologics and their cost is higher than what’s currently available, Dr. Fleischmann believes a treatment scenario of methotrexate followed by TNF-1s would be likely. “These agents would be the last ones used,” he said.

That said, Dr. Fleishmann predicted that the efficacy and safety of the kinase inhibitors will remain static with what research has found so far.

“I think, regardless of cost, most rheumatologists initially will use these medications in patients unresponsive to biologics,” Dr. Fleischmann said. “If they are successful, they will expand their use over time. Cost, patient preference, and comorbidities may lead to early adoption or avoidance.”

 


Vanessa Caceres is a freelance medical writer in Bradenton, Florida.

Page: 1 2 3 | Multi-Page
Share: 

Filed under:ConditionsDrug UpdatesMeeting ReportsResearch RheumRheumatoid Arthritis Tagged with:ACR/ARHP Annual MeetingdrugImmunologyJAK inhibitorsjanus kinaseMethotrexatepatient careRAResearchRheumatoid arthritisTofacitinibTreatment

Related Articles

    Tofacitinib with Methotrexate Not Inferior to Adalimumab with Methotrexate

    July 13, 2017

    Highlights from the 2017 EULAR Congress MADRID—Tofacitinib (a JAK inhibitor) used with methotrexate (MTX) is not inferior to adalimumab (a TNF inhibitor) plus MTX in rheumatoid arthritis (RA) patients who’ve had an inadequate response to MTX alone, according to results of a Phase 3B/4 trial presented in a session at the Annual European Congress of…

    Effectiveness of Tofacitinib with Methotrexate, Adalimumab Therapy Evaluated in Patients with RA

    September 19, 2017

    Methotrexate lyricsaima / Shutterstock.com MADRID—Tofacitinib (a JAK inhibitor) used with methotrexate (MTX) is not inferior to adalimumab (a TNF inhibitor) in rheumatoid arthritis (RA) patients who’ve had an inadequate response to MTX alone, according to results of a Phase 3B/4 trial presented in a session at the Annual European Congress of Rheumatology (EULAR). The findings…

    Tofacitinib and Other Kinase Inhibitors Offer New Approach to Treating Rheumatoid Arthritis

    June 1, 2013

    Small molecule kinase inhibitors, such as JAK inhibitors, provide a novel route for rheumatic disease treatment—and may promote our understanding of the immune system’s complexities

    Updates on JAK Inhibitor Safety, COVID-19 Vaccination in Immunosuppressed Patients & More

    December 7, 2021

    Dr. Jeffrey Curtis ACR CONVERGENCE 2021—The ACR Convergence 2021 meeting reflected the continued advancement of science and practical research in the field of rheumatoid arthritis (RA). Among the most important topics this year in RA was the evolution of the risk-benefit profile of Janus kinase (JAK) inhibitors, for which new safety data emerged in a…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
fa-facebookfa-linkedinfa-youtube-playfa-rss
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences